These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30745518)

  • 1. [Drug properties of fosravuconazole L-lysine ethanolate (NAILIN
    Nakano M; Aoki Y; Yamaguchi H
    Nihon Yakurigaku Zasshi; 2019; 153(2):79-87. PubMed ID: 30745518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.
    Watanabe S; Tsubouchi I; Okubo A
    J Dermatol; 2018 Oct; 45(10):1151-1159. PubMed ID: 30156314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis.
    Gupta AK; Leonardi C; Stoltz RR; Pierce PF; Conetta B;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):437-43. PubMed ID: 15987289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of additional oral fosravuconazole l-lysine ethanolate therapy following inadequate response to initial treatment for onychomycosis: A multicenter, randomized controlled trial.
    Naka W; Tsunemi Y
    J Dermatol; 2024 Jul; 51(7):964-972. PubMed ID: 38482989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of fosravuconazole treatment for onychomycosis refractory to topical antifungal agents.
    Inoue T; Watabe D; Tsunemi Y; Amano H
    J Dermatol; 2023 Aug; 50(8):1014-1019. PubMed ID: 37157898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Outcome with Fosravuconazole for Onychomycosis.
    Shimoyama H; Yo A; Sei Y; Kuwano Y
    Mycopathologia; 2021 May; 186(2):259-267. PubMed ID: 33754205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis.
    Yamaguchi H
    Med Mycol J; 2016; 57(4):E93-E110. PubMed ID: 27904057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fosravuconazole to treat severe onychomycosis in the elderly.
    Noguchi H; Matsumoto T; Kimura U; Hiruma M; Kano R; Kubo M; Fukushima S; Ihn H
    J Dermatol; 2021 Feb; 48(2):228-231. PubMed ID: 33099769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fungal melanonychia caused by Candida parapsilosis successfully treated with oral fosravuconazole.
    Noguchi H; Matsumoto T; Kimura U; Hiruma M; Kano R; Yaguchi T; Fukushima S; Ihn H
    J Dermatol; 2019 Oct; 46(10):911-913. PubMed ID: 31342551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terbinafine: a review of its use in onychomycosis in adults.
    Darkes MJ; Scott LJ; Goa KL
    Am J Clin Dermatol; 2003; 4(1):39-65. PubMed ID: 12477372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.
    Groll AH; Mickiene D; Petraitis V; Petraitiene R; Kelaher A; Sarafandi A; Wuerthwein G; Bacher J; Walsh TJ
    J Antimicrob Chemother; 2005 Nov; 56(5):899-907. PubMed ID: 16172108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up study of the efficacy of fosravuconazole in the treatment of onychomycosis in elderly patients.
    Okubo A; Hanada M; Kodama S; Taniguchi N; Miyazaki Y
    J Dermatol; 2024 Aug; 51(8):1091-1097. PubMed ID: 38700273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Tinea Faciei, Tinea Corporis, and Tinea Unguium with Dermatophytoma Successfully Treated with Oral Fosravuconazole L-lysine Ethanolate.
    Suzuki T; Sato T; Kasuya A; Yaguchi T
    Med Mycol J; 2021; 62(1):1-4. PubMed ID: 33642522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail.
    Lipner SR; Scher RK
    Expert Rev Clin Pharmacol; 2015; 8(6):719-31. PubMed ID: 26325488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects.
    Ishii Y; Ito Y; Matsuki S; Sanpei K; Ogawa O; Takeda K; Schuck EL; Uemura N
    Clin Transl Sci; 2018 Sep; 11(5):477-486. PubMed ID: 29768713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How effective is efinaconazole in the management of onychomycosis?
    Gupta AK; Cernea M
    Expert Opin Pharmacother; 2016; 17(4):611-8. PubMed ID: 26809447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.
    Gupta AK; Shear NH
    Drug Saf; 2000 Jan; 22(1):33-52. PubMed ID: 10647975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole.
    Noguchi H; Matsumoto T; Hiruma M; Kimura U; Kano R; Yaguchi T; Fukushima S; Ihn H
    J Dermatol; 2019 Dec; 46(12):e446-e447. PubMed ID: 31353607
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics of antifungal agents in onychomycoses.
    Debruyne D; Coquerel A
    Clin Pharmacokinet; 2001; 40(6):441-72. PubMed ID: 11475469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.
    Watanabe S; Kishida H; Okubo A
    J Dermatol; 2017 Jul; 44(7):753-759. PubMed ID: 28332720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.